Polymeric Liposomal Formulation for Keratitis

• Enhances corneal bioavailability and prolongs residence time of antimicrobial drugs via polymeric liposomal delivery.
• Provides sustained and controlled drug release, maintaining therapeutic levels for longer duration.
• Reduces dose and dosing frequency, improving patient compliance.
• Minimizes systemic exposure and toxicity, particularly for drugs like amphotericin B.
• Offers a non-invasive, corneal-targeted eye drop formulation for effective keratitis treatment with reduced time to cure.

• A polymeric liposomal eye drop formulation for treating keratitis effectively.
• Composed of lipids, cholesterol, CSA polymer, and antimicrobial agents.
• Enhances corneal drug penetration and ocular retention.
• Ensures controlled release, reducing both dose and dosing frequency.
• Improves therapeutic efficacy while reducing systemic toxicity.

• Enhanced treatment effect while reducing dose and dosing frequency.
• Prolonged ocular residence to improve keratitis treatment outcomes.
• Sustained therapeutic effect from controlled drug release.
• Easy administration and improved patient compliance.